Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:artemisinin-based_therapies
gptkb:Plasmodium_falciparum gptkb:artesunate |
| gptkbp:activities |
inhibits heme polymerization
|
| gptkbp:approves |
gptkb:1989
gptkb:FDA |
| gptkbp:availability |
prescription only
|
| gptkbp:brand |
gptkb:Lariam
|
| gptkbp:category |
gptkb:C
|
| gptkbp:class |
quinoline
|
| gptkbp:clinical_trial |
Phase IV
Phase III |
| gptkbp:composed_of |
synthetic compound
|
| gptkbp:contraindication |
history of psychiatric disorders
history of seizures |
| gptkbp:developed_by |
gptkb:Walter_Reed_Army_Institute_of_Research
|
| gptkbp:dosage_form |
15 mg/kg for treatment
250 mg once a week |
| gptkbp:duration |
3 days for acute malaria
4 weeks for prophylaxis |
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
mefloquine
|
| gptkbp:ingredients |
C17 H16 Cl2 F N3 O
|
| gptkbp:interacts_with |
antidepressants
beta-blockers anticonvulsants |
| gptkbp:is_atype_of |
P01 B C03
|
| gptkbp:is_used_for |
treatment of malaria
prevention of malaria |
| gptkbp:lifespan |
approximately 20 days
|
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
gptkb:Lariam
|
| gptkbp:metabolism |
liver
|
| gptkbp:name |
essential medicines
|
| gptkbp:research_areas |
malaria prevention
treatment of drug-resistant malaria |
| gptkbp:safety_features |
post-marketing surveillance
|
| gptkbp:side_effect |
gptkb:historical_event
anxiety dizziness fatigue headache nausea abdominal pain fever vomiting gastrointestinal disturbances rash insomnia cardiac arrhythmias hepatotoxicity visual disturbances |
| gptkbp:water_resistance |
possible with prolonged use
|
| gptkbp:year_created |
1970s
|